Paul Hartmann AG Stock
€197.00
Your prediction
Paul Hartmann AG Stock
Pros and Cons of Paul Hartmann AG in the next few years
Pros
Cons
Performance of Paul Hartmann AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Paul Hartmann AG | 0.000% | -0.253% | 3.141% | -5.742% | -3.902% | -46.467% | -32.993% |
| Eckert & Ziegler Strahlen- und Medizintechnik AG | -0.300% | -2.642% | -3.014% | 30.774% | -1.935% | -70.495% | -8.177% |
| Geratherm Medical AG | -1.710% | -10.980% | 24.044% | -29.612% | -16.697% | -53.579% | -43.951% |
| Stratec SE | 4.350% | -8.324% | 0.626% | -15.368% | -12.418% | -71.610% | -41.142% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Taking a first look at the financials of Paul Hartmann (PLHNF), it's immediately clear that this is a company with a solid financial backbone. Demonstrating consistently high figures across the board in terms of total assets, gross profit, and operating income. It's equally apparent that this healthcare equipment and supplies provider is a key player in its industry.
The recorded total assets for Paul Hartmann have shown steady growth from 2020 through to 2022. This trend signifies an important aspect of company health, indicating that PLHNF is expanding. Gross profits also appear to be on the rise, suggesting that the company is efficiently managing its cost of goods sold and generating a healthy income.
Another optimistic signal is the company's positive net income, demonstrating that the company is not only generating revenue but is also profitable. This is further validated by the positive figures in net income from continuing operations, a crucial factor for investors looking for long-term profitability.